Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eltrekibart · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Eltrekibart + Placebo | EXPERIMENTAL | Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab. |
| Mirikizumab + Placebo | EXPERIMENTAL | Participants will receive mirikizumab and placebo or mirikizumab. |
| Eltrekibart + Mirikizumab | EXPERIMENTAL | Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy. |
| Placebo | EXPERIMENTAL | Participants will receive placebo or mirikizumab. |
| Eltrekibart Dose 1 | EXPERIMENTAL | Eltrekibart will be given subcutaneously (SC). |
| Eltrekibart Dose 2 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Eltrekibart Dose 3 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Name | Type | Description |
|---|---|---|
| Eltrekibart | DRUG | Administered |
| Mirikizumab | DRUG | Administered |
| Placebo | DRUG | Administered |
Inclusion Criteria: * Have had an established diagnosis of UC of ≥3 months in duration before baseline. * Have moderately to severely active UC as assessed by the UC disease activity score. * Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Eltrekibart is an investigational small molecule being studied for ulcerative colitis and hidradenitis suppurativa. In hidradenitis suppurativa, it is being evaluated in adults with moderate to severe disease. In ulcerative colitis, it is being studied in adults with moderately to severely active disease.
Eltrekibart is being developed by Eli Lilly and Company, traded on the New York Stock Exchange under the ticker LLY. The company is conducting clinical trials of the drug in both ulcerative colitis and hidradenitis suppurativa.
Eltrekibart is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or recently completed to evaluate its safety and efficacy in ulcerative colitis and hidradenitis suppurativa.
Eltrekibart is being studied in two Phase 2 trials. NCT06046729, completed, enrolled 352 adults with moderate to severe hidradenitis suppurativa. NCT06598943, currently recruiting, is studying Eltrekibart and mirikizumab in 143 adults with moderately to severely active ulcerative colitis.
Yes, Eltrekibart is also known as LY3041658. The completed hidradenitis suppurativa trial NCT06046729 refers to the drug as Eltrekibart (LY3041658), confirming that both names identify the same investigational compound.